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doi:10.101Consensus Conference on Clinical Practice in Chronic
Graft-versus-Host Disease (GVHD): First-Line and
Topical Treatment of Chronic GVHD
Daniel Wolff,1 Armin Gerbitz,2 Francis Ayuk,3 Alexander Kiani,4
Gerhard C. Hildebrandt,1 Georgia B. Vogelsang,5 Sharon Elad,6 Anita Lawitschka,7
Gerard Socie,8 Steven Z. Pavletic,9 Ernst Holler,1 Hildegard Greinix10Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation is still
associated with significant morbidity and mortality. First-line treatment of cGVHD is based on steroids of
1 mg/kg/day of prednisone. The role of calcineurin inhibitors remains controversial, especially in patients
with low risk for mortality (normal platelets counts), whereas patients with low platelets at diagnosis and/
or high risk for steroid toxicity may be treated upfront with the combination of prednisone and a calcineurin
inhibitor. Additional systemic immunosuppressive agents, like thalidomide, mycophenolic acid, and azathio-
prine, failed to improve treatment results in the primary treatment of cGVHD and are in part associated with
higher morbidity, and in the case of azathioprine, with higher mortality. Despite advances in diagnosis of
cGVHD as well as supportive care, half of the patients fail to achieve a long-lasting response to first-line treat-
ment, and infectious morbidity continues to be significant. Therefore, immunomodulatory interventions with
low infectious morbidity and mortality such as photopheresis need urgent evaluation in clinical trials. Beside
systemic immunosuppression, the use of topical immunosuppressive interventions may improve local re-
sponse rates and may be used as the only treatment in mild localized organ manifestations of cGVHD.
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6/j.bbmt.2010.06.015is the leading cause for latemortality after allogeneic he-
matopoietic stem cell transplantation (allo-HSCT)
[1,2]. Moreover, because of rising recipient age, and
the use of unrelated donors as well as peripheral blood
stem cells (PBSCs) as a graft source, the incidence of
cGVHDhas been increasing [3]. Althoughmajor prog-
ress has been achieved in understanding the pathophys-
iology of acute GVHD (aGVHD), cGVHD is far less
defined. Current concepts include the persistence of
alloreactive T cells, a Th1-Th2 shift of the cellular im-
mune response, defective peripheral, and central toler-
ance mechanisms (ie, failure of control by regulatory
T cells and/or impaired negative selection of T cells in
the thymus), replacement of antigen presenting cells
(APCs) of the host by APCs of the donor leading to in-
direct antigen presentation of allo-antigens, an increas-
ing role of B cells producing auto- and allo-antibodies
against the host, and unspecific mechanisms of chronic
inflammation leading to fibrosis of involved organs [4].
First-line treatment of cGVHDconsistsmainly of pred-
nisone with a starting dose of 1 mg/kg/day, often com-
bined with a calcineurin inhibitor (CNI). Evidence for
first-line treatment options is based on controlled trials
with the exception of severe cGVHD, which continues
to be associatedwith interior survival [1].Until recently,1611
Table 1. Strength of Recommendation
Strength of
Recommendation
Level Definition of Recommendation Level
A Should always be offered
B Should generally be offered
C Evidence for efficacy is insufficient to support
for or against, or evidence might not outweigh
adverse consequences, or cost of the
approach. Optional
C-1* Use in first-line treatment justified
C-2* Use in equal to or greater than second-line
treatment justified
D Moderate evidence for lack of efficacy or
for adverse outcome supports
a recommendation against use.
Should generally not be offered.
*Only applied for topical treatment of chronic graft-versus-host disease
(cGVHD).
Table 2. QualityofEvidenceSupporting theRecommendation
Strength of
Evidence Level Definition of Evidence Level
I Evidence from $1 properly randomized, controlled trial
II Evidence from >1 well-designed clinical trial without
randomization, from cohort or case-controlled analytic
studies (preferable from >1 center) or from multiple
time series or dramatic results from uncontrolled
experiments
III Evidence from opinions of respected authorities based on
clinical experience, descriptive studies, or reports from
expert committees
III-1* Several reports from retrospective evaluations or small
uncontrolled clinical trials
III-2* Only 1 report from small uncontrolled clinical trial
or retrospective evaluations
III-3* Only case reports available
*Only applied for topical treatment of chronic graft-versus-host disease
(cGVHD).
1612 Biol Blood Marrow Transplant 16:1611-1628, 2010D. Wolff et al.novalid criteria for thediagnosis and stagingof cGVHD
severitywere available,which limits the valueofmost re-
ported trials on the treatmentof cGVHD.TheNational
Institutes of Health (NIH) consensus criteria on diag-
nosis and staging of cGVHD as well as on treatment re-
sponse criteria, reported in 2005, provide defined
criteria that should improve the validity of reported re-
sults on treatment of cGVHD in the future [5-9].
Despite available evidence from controlled studies, no
consensus has been achieved on first-line treatment
of cGVHD. The Consensus Conference on Clinical
Practice in Chronic GVHD held in fall of 2009 in Re-
gensburg, Germany (complete program provided at
www.gvhd.de), aimed to summarize the current avail-
able evidence for first-line and topical treatment and
to provide practical guidelines for the use of treatment
modalities. The presented consensus was based on a re-
view of published evidence and a survey on the current
clinical practice including transplant centers from
Germany, Austria, and Switzerland. Moreover, the
consensus was circulated among all transplant centers
performing allo-HSCT in Germany, Austria, and
Switzerland, and was discussed during the Consensus
Conference meetings. The Consensus Conference was
organized under the auspices of the German working
group on bonemarrow and blood stem cell transplanta-
tion (DAG-KBT) and theGerman Society ofHematol-
ogy and Oncology (DGHO), the Austrian Stem Cell
Transplant Working Group of the Austrian Society of
Hematology and Oncology, the Swiss Blood Stem Cell
Transplantation Group (SBST), and the German-
Austrian Paediatric Working Group on SCT.
The evaluation of evidence and the subsequent rec-
ommendation was graded according to the system used
in grading of supportive care published by Couriel [10].
The evidence of the majority of treatment options in
cGVHD is sparse, and, therefore, for most of the thera-
peutic options the strength of recommendation falls
into category C. In addition, category C and evidence
III level were further specified as shown in Tables 1
and 2. All recommendation and evidence levels were
first rated by an expert panel and subsequently rated
by all participants of the consensus process. Only
evidence from the use in cGVHD was included in the
evaluation.
According to the number and severity of organs
involved with cGVHD, the NIH consensus defined
mild cGVHD as mild involvement of 2 organs only,
excluding lung involvement, moderate cGVHD as
mild involvement of more than 2 organs, or moderate
organ involvement excluding moderate lung involve-
ment, and severe cGVHDas any severe organmanifes-
tation or moderate lung manifestations [8].
Here, we discuss first-line and topical treatment op-
tions for cGVHD.Wemainly focus on reported clinical
trials and retrospective analyses. The literature search
was performed by the working group on first-linetreatment within the Consensus Conference using the
Pubmed database. Only English literature was consid-
ered. Abstracts from theBoneMarrowTransplantation
Tandemmeetings, the European BoneMarrowTrans-
plantation meetings, and the American Society of He-
matology meetings were cited, but were not included
in the evidence rating.
Principles of First-Line Treatment of cGVHD
As the diagnosis of cGVHD has major conse-
quences on the further clinical course of the patient,
the diagnosis needs to be based on either diagnostic
clinical signs of cGVHD or requires confirmation by
histology as described by the NIH consensus as well
as the consensus within the German/Austrian/Swiss
Bone Marrow Transplantation Group [8]. Once diag-
nosis of GVHD is established, the first step is to distin-
guish classic cGVHD from overlap syndrome or late
aGVHD. Especially in the latter situation as for overlap
syndrome with dominating acute features, treatment
should be applied according to standard practice in
treatment of aGVHD (ie, treatment with steroids in
Table 3. Severity Grading of cGVHD
Severity Mild Moderate Severe
Number of involved
organs
1-2 $3 $3
Severity of organ
manifestations
1 (excluding lung) 2 (or lung 1) 3 (or lung 2)
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overlap syndrome with evenly balanced symptoms still
need to be defined. While aGVHD is defined by the
presence of exclusive features of aGVHD, the diagnosis
of overlap syndrome is based on the simultaneous pres-
ence of symptoms of aGVHD and distinctive or diag-
nostic features of cGVHD [8]. The diagnosis of
classic cGVHDrequires the presence of either diagnos-
tic or distinctive symptoms of cGVHD in the absence
of features of aGVHD [8].
The Consensus Conference on Clinical Practice of
Chronic GVHD focused on treatment of classic
cGVHD. Prognostic features at diagnosis of cGVHD
have been described. The presence of thrombocytope-
nia or direct progression from aGVHD have been
associated with adverse outcome [1]. The value of
“progressive onset” as a risk factor is limited by the
fact that traditionally any GVHD being present at
day 100was documented as cGVHD.However, 2 stud-
ies reclassifying GVHD according to the NIH criteria
revealed a significant proportion of patients being tra-
ditionally classified as cGVHD instead of late aGVHD
[11,12]. The risk factor “thrombocytopenia” has been
identified in cohorts receiving a myeloablative (MA)
conditioning regimen and mainly bone marrow (BM)
as a graft source [1]. Therefore, it remains to be shown
whether low platelets remain as a risk factor in patients
receiving nonmyeloablative regimens and PBSCs as
a graft source. Additional risk factors are extensive
skin disease (.50% body surface) as well as severe
cGVHD (NIH grading) [1]. A detailed classification
of cGVHD severity according to the NIH consensus
is delineated in Table 3 [8].
As for treatment, prognosis of overlap syndrome is
a matter of debate as well; Jagasia and colleagues [13]
reported a significantly worse survival of patients
with any features of aGVHD after day 100 of HSCT
compared with cGVHD. This is in contrast to reports
by Arora et al. [11] and Cho et al. [12], stating no sig-
nificant survival difference in patients with overlap
syndrome compared to classic cGVHD and to a retro-
spective analysis published by Vigorito et al. [14], dem-
onstrating no significant survival differences between
patients with late aGVHD and cGVHD.
Currently, no uniformly accepted definition of ste-
roid refractory cGVHD is available. Generally, ac-
cepted criteria for steroid refractory cGVHD are (1)
progression despite immunosuppressive treatment us-
ing 1 mg/kg/day of prednisone for 2 weeks, (2) stable
disease if 4 to 8 weeks on $0.5 mg/kg/day of predni-
sone, and (3) inability to taper below 0.5 mg/kg/day
of prednisone. Treatment duration may vary depend-
ing on clinical manifestation (sclerosis requires longer
to respond) or toxicity (shorter duration in the presence
of significant toxicity) [9,15]. In the presence of primary
treatment failure, alternative treatment options need to
be started.Treatment of Mild cGVHD
During the Consensus Conference on Clinical
Practice of Chronic GVHD, an agreement was
achieved that mild cGVHD may be treated either
with topical immunosuppressive agents or with sys-
temic steroids alone. In the scenario of solely topical
immunosuppression, a close follow-up and screening
for any potential manifestation of cGVHD is crucial
to detect systemic progression of cGVHD during top-
ical treatment. An additional factor influencing the de-
cision of treatment of choice is the risk for relapse of
the underlying malignancy, supporting topical treat-
ment in the presence of a high relapse risk.
In pediatric patients, 2 additional considerations
have to be taken into account. Side effects of systemic
steroid therapy can be deleterious on a growing child.
On the other hand, patients with nonmalignant under-
lying diseases have no benefit from the cGVHD-
associated graft-versus-leukemia (GVL) effect even
in mild disease courses. Therefore, topical therapy
should be offered as often and as early as possible.
Mildmanifestations of cGVHD that cannot be suf-
ficiently treated by topical treatment such as hepatic
manifestations or fasciitis may be treated with systemic
corticosteroids alone. Again, lower initial doses than 1
mg/kg/day of prednisonemay be used, but evidence for
or against a reduced dose of steroids is virtually absent.
In the presence of a high risk of relapse, an approach
using supportive treatment with either nonsteroidal
anti-inflammatory drugs (involvement of fascia or
joints) or ursodeoxycholic acid (hepatic disease) may
be suitable treatment options as long as a close
follow-up to detect progression is guaranteed.
Because treatment is rather symptomatic and does
not aim to control a systemic process, topical treat-
ment should be continued as long as symptoms are
present andmay be tapered and withdrawn in the pres-
ence of remission of symptoms. The same applies for
systemic treatment, although treatment for at least 4
to 8 weeks should be given to avoid frequent relapses
of symptoms of cGVHD.Treatment of Moderate cGVHD: Role of
Prednisone (A I)
Treatment of moderate cGVHD requires systemic
immunosuppression. Additional topical treatmentmay
be applied to speed up the response or to improve local
response rates, but it does not replace the requirement
Table 4. First-Line Treatment Options in cGVHD
Agent
Recommendation
(citation number
of references) Evidence Side Effects Comments
Steroids A [16-18] I Osteoporosis, avascular necrosis
of the bone, diabetes
Important but need to spare steroids because
of side effect profile, generally sufficient in primary
treatment of mild cGVHD as single agent, may be
used in combination with CNI in moderate
or severe cGVHD
CNI C [16,17] II Renal toxicity, hypertension Only be used in combination with steroids, spares steroids,
lower rate of avascular necrosis of the bone, may be
considered in combination with steroids in primary
treatment of severe cGVHD as well as in CNI
dependent moderate cGVHD
MMF in triple agent
combinations
D [19] II GI complaints, infectious and relapse risk Failure to improve efficacy in a randomized trial
documented
Azathioprine D [18] II Hematologic toxicity, infectious risk Adverse outcome in a randomized trial in combination
with steroids
Thalidomide D [20,21] II Neurotoxicity, sedation, constipation,
thrombosis
May be used in concomitant relapse of multiple myeloma
CNI indicates calcineurin inhibitors; MMF, mycophenolate mofetil; GI, gastrointestinal; cGVHD, chronic graft-versus-host disease.
1614 Biol Blood Marrow Transplant 16:1611-1628, 2010D. Wolff et al.for systemic immunosuppression. Standard treatment
is 1 mg/kg/day of prednisone or an equivalent dose of
methylprednisolone. So far, no other treatment option
replacing steroids in first-line treatment has been eval-
uated, resulting in a grade A recommendation with an
evidence grade of I, although a steroid-free approach
has never been applied [16-18]. Steroid dependence
of the majority of patients failing first-line treatmentTable 5. Topical Immunosuppressive Treatment Options in cGVH
Organ
Agent (citation number
of references) Recommendation Evidence
Skin Topical steroids [7] C-1 III-1
Tacrolimus/Pimecrolimus [22-25] C-1 III-1
PUVA [26-31] C-1 III-1
UVA [32-35] C-1 III-1
UVB [36] C-1 III-2
GI Topical steroids [37-39] C-1 III-1
Lung Topical steroids B III-2
Oral Topical steroids [40-44] C-1 III-1-III-3
Topical tacrolimus /cyclosporine [45-51] C-2 III-1
Topical PUVA/UVB [44,52-54] C-2 III-1
Eye Topical steroids [55,56] C-1 III-1
Topical cyclosporine [57-60] C-1 III-1
Vaginal Topical steroids [61-64] B III-3
Topical tacrolimus/
cyclosporine/pimecrolimus [63-65]
B III-3
cGVHD indicates chronic graft-versus-host disease.indicates the central role of steroids in treatment of
cGVHD (Tables 4).
A first report in the early 1980s indicated that
prednisone alone or in combination with other immu-
nosuppressive agents (particularly azathioprine and
cyclophosphamide) could improve the outcome of pa-
tients who required treatment for extensive cGVHD
[66]. A randomized double-blinded study comparingD
Side Effects Comments
Skin atrophy Neck down: mid-strength steroids if no
response upper strength steroids,
face: hydrocortisone 1%
Long-term risk for
cutaneous malignancies
Should be given twice daily
Phototoxicity, risk for
cutaneous malignancies
Should not be used with phototoxic
medication
Phototoxicity, risk for
cutaneous malignancies
Requires no UV protection after
treatment, should not be used with
phototoxic medication
Phototoxicity, risk for
cutaneous malignancies
Only effective in lichenoid cGVHD
Either budesonide or beclomethasone
May be combined with betamimetic
agents
Best results with topical
budesonide
Requires oral hygiene and possibly
topical antifungals
Burning Potentially increases risk for oral
malignancies, may be combined
with topical steroids
Optional treatment option for
refractory manifestations
Psoralene may be given topically
or systemically
Risk for corneal thinning and
infectious keratitis
Duration of exposure should be limited
Burning, stinging Fewer long-term side effects
compared to steroids, high
long-term efficacy
Increased risk for infectious
complications and atrophy
Topical estrogen application and
antifungal prophylaxis suggested
Burning Less well tolerated but better
long-term efficacy
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oprine in patients with platelet counts .100,000/mL
showed better outcome with prednisone alone, and
thus established prednisone as the treatment of choice
for patients with standard-risk extensive cGVHD [17].
The central role of prednisone was further confirmed
by a randomized trial comparing prednisone alone ver-
sus prednisone and cyclosporine (CsA) in patients with
extensive cGVHD and platelet counts .100,000/mL
showing no difference in overall survival (OS) in the
2 arms and no better control of cGVHD [16].
Starting in the 1980s, the standard initial steroid
dose for the treatment of cGVHD has been 1 mg/kg/
day, regardless of whether prednisone was used alone
or in combination with other drugs [17,18,66]. There
are no randomized studies comparing this dose with
higheror lower initial doses.Recent retrospective analy-
ses of patients with aGVHD indicate that 1 mg/kg/day
could be at least as effective as 2 mg/kg/day for
patients with grades I-1I aGVHD [67]. Considering
the need for protracted treatment of cGVHD, it may
be worthwhile exploring lower doses of steroids. Pend-
ing such studies 1mg/kgdaily is considered the standard
initial dose.
The Seattle group suggests tomaintain this dose for
2 weeks and then to taper to 1 mg/kg every other day
over a period of 6 to 8 weeks if symptoms are stable or
improving, and then either maintain this dose for 2 to
3 months or continue straight on to taper by 10% to
20% per month [68]. The survey sent to all centers
participating in the Consensus Conference revealed
that 26 of 31 centers (84%) start to reduce the steroid
dose after 2weeks of treatment if symptoms are inactive.
G. Vogelsang [15], from the Johns Hopkins group,
reported that 90% of responding patients would have
done so within 3 months after achieving the alternate-
day dose; thus, a reevaluation of patients at this stage
should guide further tapering. Patients with complete
responses (CRs) should be further tapered 10% to
20% monthly, whereas those still responding should
stay on 1 mg/kg for about another 3 months after
achieving maximum response and then slowly be ta-
pered as described. If symptoms flare during tapering,
increasing the steroid dose may again induce response.
Patients who by the 3-month reevaluation have not re-
sponded should be considered for alternative treatment
strategies [15,68].
Since the early 1960s, alternate dosing of steroids
has been considered an effective regimen for the treat-
ment of many immune-mediated disorders. The dose-
spacing is thought to maintain efficacy while reducing
toxicity of the applied steroids [69]. However, there are
no randomized studies comparing daily and alternate-
day strategies in cGVHD. In kidney transplant
patients, the alternate-day dosing reduces the level of
plasma lipids [70]. Likewise, administration of steroids
as a single dose in the morning instead of a split doseis meant to match the circadian cycle and reduce side
effects. Randomized studies in children treated with
prednisolone for nephrotic syndrome and adults
treated for proctocolitis showed similar efficacy of sin-
gle compared to split-dose strategies [71,72]. Whether
this holds true for patients being treated for cGVHD
still has to be demonstrated in prospective studies.
There are no studies comparing the effects and side
effects of prednisone to other systemic steroid
preparations such as methylprednisolone in patients
with cGvHD.Role of CNIs (C II)
Although the role of steroids in first-line treatment
is well established, the role of CNIs is less clear. The
potential benefit of the CNIs CsA and tacrolimus
(FK506) in the treatment of cGVHD has been
addressed in a small number of studies [16,17]. In
a nonrandomized trial conducted more than 20 years
ago, Sullivan et al. [17] added an alternating-day sched-
ule of CsA (6 mg/kg twice a day) to a previously estab-
lished alternating-day regimen of 1 mg/kg prednisone
to treat 40high-risk patientswithnewly diagnosedmul-
tiorgan cGVHDand thrombocytopenia\100,000/mL.
After 9 months a CR rate of 33% and 4-year survival of
51% were reported. These results compared favorably
to a 16%CR and 26% survival rate of a cohort of 38 pa-
tients with cGVHD and thrombocytopenia treated by
the same center in a similar period of time. This study
constituted the basis for the inclusion of CNIs to the
therapeutic regimens for cGVHD in clinical practice
for many years [15,68,73].
However, this practicewas challengedby a random-
ized trial, in which Koc and colleagues [16] compared
CsA alternating with prednisone every other day to
alternate-day prednisone alone in 287 patients with
newly diagnosed cGVHD and a platelet count
.100,000/mL [16]. The primary endpoint of this study
was the incidence of treatment-related mortality
(TRM) at 3 years, which was not different between
both groups. There was also no significant difference
with respect to the incidence of secondary therapy,
the discontinuation of immunosuppression, the inci-
dence of recurrent malignancy, or OS in this study. In
contrast, patients treated with CsA and prednisone
showed a significantly inferior survival without recur-
rentmalignancy (progression-free survival [PFS]) com-
pared to patients treated with prednisone alone. In
addition, a small subset of high-risk patients with
progressive onset cGVHD displayed a tendency for
increased TRM and inferior survival at 5 years in the
CsAplus prednisone (16patients) versus theprednisone
alone (29 patients) arm.A significantly decreased rate of
avascular necroses in patients treated in the combina-
tion arm was observed, suggesting that the addition of
CsA to the therapeutic regimen resulted in lower
1616 Biol Blood Marrow Transplant 16:1611-1628, 2010D. Wolff et al.cumulative doses of prednisone and a decreased inci-
dence of complications related to steroid treatment.
Although the studypublished byKoc et al. provided im-
portant information, it needs to be mentioned that all
patients in the study received BM grafts following MA
conditioning. Because it is known that the use of non-
myeloablative conditioning regimens influences the
presentation of cGVHD and that PBSC grafts result
in prolongedneed for treatment of cGVHDwhencom-
pared to BM, at this point it remains unclear whether
the combination of steroids with a CNI is of advantage
in the latter population [74,75]. Moreover, within the
published trials, CNIs have been dosed with an every
other day schedule without dose correction according
to plasma levels, which differs from current practice
with daily application and dose adjustments according
to plasma levels.
Limited published experience is available with
respect to the role of FK506 for first-line treatment
of cGVHD.
In summary, evidence for the use of CNIs for treat-
ing newly diagnosed cGVHD patients is scarce and,
based on the randomized trial by Koc et al. [16], cannot
generally be recommended. In standard-risk patients
(de novo or quiescent cGVHD, platelet counts
.100.000/mL), the use of CsA in addition to steroids
may be considered for those patients who are at high
risk for glucocorticoid-usage-related complications
(eg, based on age, sex, and/or the presence of comor-
bidities). Even though a direct comparison of CsA
and FK506 in the treatment of cGVHD is lacking, clin-
ical and indirect evidence suggests that both CNIs
may be equally effective in this setting [19,76]. Serum
concentrations of CsA or FK506, as well as creatinine
and other clinical or laboratory signs of adverse
events, should be monitored regularly because of
associated drug toxicity. As there are no data showing
a superiority of the alternating-day schedule, daily
administration of CsA and FK506 is generally em-
ployed in clinical practice [16,17]. Caution should be
advised, however, that some oral formulations of
CsA (eg, Sandimmun optoral) provide an improved
bioavailability of the drug, and therefore, may result
in increased serum concentrations. FK506 clearance
is age dependent in pediatric patients, and especially
children younger than 6 years of age have a higher
clearance [77].
The role of CNIs in high-risk cGVHD (ie, pro-
gressive onset and/or with thrombocytopenia [platelet
count\100,000/mL]) is unclear. The initially promis-
ing historic data of Sullivan et al. [17] on patients
with cGVHD and thrombocytopenia, including
amore recent update [78], cannot be readily transferred
to current patient cohorts, considering the change in
transplantation practice in the past 20 years.Therefore,
more randomized studies are clearly warranted to
clarify these issues.Treatment of Severe cGVHD
In general, treatment of severe cGVHD follows the
same rules as treatment of moderate cGVHD. Severe
cGVHDhas been associated with an increasedmortal-
ity and may require prolonged immunosuppression
[79]. Therefore, the combination of steroids with
aCNImay be of potential advantage in severe cGVHD
to spare steroids [16]. Furthermore, patients with
severe de novo or quiescent onset of cGVHD after
withdrawal of the CNI may be CNI dependent and
may benefit from treatment with a combination of ste-
roids with a CNI, but data evaluating this approach are
virtually absent. Although the randomized trials on
triple-agent first-line treatment of cGVHD did not
differentiate the response rate according to the extent
of organ manifestations, there is no indication that
a triple-agent approach leads to an improved response
rate and outcome in severe cGVHD [19-21].
Whether a 2-agent combination consisting of
prednisone and an additional non-CNI agent such as
mycophenolate mofetil (MMF), mTOR inhibitors, or
extracorporeal photopheresis (ECP) improves the out-
come has not been evaluated yet. Because the combina-
tion of prednisone and azathioprine resulted in an
improved response rate but significantlyworse survival,
any alternative combination urgently requires its eval-
uation in a clinical trial [18]. As ECP has not been asso-
ciated with an increased risk for infectious morbidity
and mortality, it may be a promising candidate to be
evaluated as a new combination partner with cortico-
steroids and may be a treatment option in first-line
treatment, when contraindication for CNIs exist and
high steroid-related toxicity must be expected [80,81].Treatment of Progressive Onset of cGVHD
Progressive onset of cGVHD is characterized by
direct progression of active symptoms of aGVHD into
symptoms of cGVHD during treatment of aGVHD
and has been historically associated with a dismal out-
come [1].Themajorityofpatientswithprogressiveonset
of cGVHD are on a CNI and steroids during onset of
symptoms of cGVHD. Therefore, other treatment
strategies need to be considered. Most of the 31 trans-
plant centers responding to the survey on treatment of
cGVHDreported, thatwhenprogressiveonset cGVHD
evolved during the taper of steroids and despite being on
a CNI, treatment involved a temporary increase of the
steroid dose and the addition of a new agent such as
MMF or ECP to the CNI. The reported increased
morbidity andmortality because of infectious complica-
tions when using the triple-agent combination of pred-
nisone, a CNI, and MMF indicate the limitation of
this approach [19]. Because of the low risk for infectious
complications, ECP therefore may be a promising can-
didate for clinical trial evaluation treating cGVHD de-
veloping during treatment of aGVHD [80,81]. Other
Biol Blood Marrow Transplant 16:1611-1628, 2010 1617First-Line and Topical Treatment of Chronic GVHDpotential alternativesmaybe the replacementof theCNI
by a mTOR inhibitor.
Azathioprine (DII)
Although responses of cGVHD to azathioprine
have been documented, a double-blinded randomized
trial comparing prednisone 1 placebo versus predni-
sone1 azathioprine in standard risk cGVHD (platelets
.100 000/mL) revealed a significantly increased nonre-
lapse mortality (40% versus 21%) and a significantly
decreased OS (47% versus 61%) [18]. Therefore, aza-
thioprine should not be used as first-line therapy in
combination with steroids in patients with cGVHD.
Thalidomide (DII)
Although thalidomide displays therapeutic activity
in second-line treatment of cGVHD, 2 randomized tri-
als evaluating the efficacy of thalidomide in first-line
treatment of cGVHD failed to show any advantage for
the addition of thalidomide to standard immunosup-
pression with CsA and prednisone [20,21]. Arora et al.
[20] published the results of a randomized trial compar-
ing standard treatment with CsA and prednisone with
additional thalidomide (dose range: 200-800 mg/day)
in 1 arm in adult patients with newly diagnosed
cGVHD. Each arm contained 27 patients and achieved
identical response rates with 88% versus 84% after 6
months. Although mortality was not increased in the
arm containing thalidomide, frequent side effects like
constipation, sleepiness, and neuropathy attributable
to thalidomidewhere observed.Koc et al. [21] published
a second randomized trial comparing CsA and predni-
sone with additional thalidomide (each study arm
contained 26 patients) in primary treatment of high-
risk cGVHD (low platelets or progressive onset of
cGVHD). Because of a high rate of side effects (doses
.200 mg/day of thalidomide were not tolerated), tha-
lidomidewasprematurely terminated in93%ofpatients
(median on day 53). Themost frequent side effects were
neuropathy and neutropenia.
MMF
AlthoughMMF is frequently applied in second-line
treatment of cGVHD, its use in first-line treatment is
lesswell established [68]. A randomizedprospective trial
by Martin et al. [19] has been recently published where
placebo-controlled MMF was added within 14 days as
first-line treatment after diagnosis in combination
with CsA, FK506), or sirolimus. Most of the reported
151 patients also received prednisone at an initial dose
of 1 mg/kg/day. Treatment success was very stringently
defined aswithdrawal of all systemic treatment after res-
olution of all reversible manifestations of cGVHD. OS
trended to be lower in the treatment arm (87% versus
74%). The first-line use of MMF did not increase the
proportion of patients who displayed resolution ofcGVHD.Furthermore,MMF treatment was associated
with increased risk of thrombocytopenia, but, more im-
portantly, with a trend toward higher rates of recurrent
malignancies and infections. The suspected negative
impact of MMF on GVL effects in combination treat-
ment seemed to have influence in this study especially
in combination with steroids. Interestingly, the use of
MMF did not influence the amount of systemic gluco-
corticoid treatment. Because the randomized trial did
not include patients with progressive onset cGVHD,
it remains unresolved whether MMF might be active
in primary treatment in this situation. Given the poor
prognosis of this specific patient subpopulation, further
controlled trials are warranted.
At this point, it is suggested that MMF does not
add any benefit to first-line treatment of cGVHD
when used as part of a triple agent regimen, but it
may be used if steroid and CNI doses are reduced.
Moreover, MMF has not been evaluated in combina-
tion with steroids only, for example, as a replacement
for CNI in the initial therapy and may represent a suit-
able treatment alternative in situations with a high
need to spare steroids especially in pediatric patients.
ECP
So far, published evidence on the use of ECP for
treatment of cGVHD almost exclusively consists of pa-
tients with steroid-refractory or steroid-dependent dis-
ease [80-85]. Based on the excellent safety profile of
ECP and frequently reported evidence that the GVL
effect seems not to be impaired by ECP, leading
experts in the field of allogeneic HSCT recommend
the use of ECP earlier in the course of cGVHD
[86,87]. Also, in clinical practice guidelines based on
clinical experience Kanold and colleagues [88] consid-
ered ECP as first-line therapy of pediatric patients
with limited cGVHD. Currently, a prospective phase
II study is ongoing at the Medical University of Vienna
(NCT00271869), recruiting patients with newly diag-
nosed liver or lung involvement by cGVHD, to investi-
gate adjunct ECP. In another ongoing prospective
phase II study (NCT00048789) ECP is investigated in
cGVHD patients earlier in the course of their disease.
In view of the poor prognosis of patients with re-
fractory cGVHD and the promising results of ECP
obtained with almost no severe side effects, it is tempt-
ing to assume that ECP in first-line therapy will sub-
stantially improve patients’ outcome. However, data
on prospective controlled trials are currently lacking,
and thus, studies investigating upfront use of ECP in
well-defined patient populations are highly warranted.
Results of the Survey on First-Line Treatment
of cGVHD
Thirty-one of 37 transplant centers performing allo
HSCT within Germany (n 5 34), Austria (n 5 3), and
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survey sent via e-mail to representatives of the centers.
The survey was sent in June 2009 to representatives
of 37 transplant centers performing allo HSCT to
document the current practice prior to the Consensus
Conference and to identify areas of disagreement
between transplant centers.
Treatment of mild cGVHD
The majority of centers (67%) stated the use of
solely topical immunosuppression in mild cGVHD
that can be reached by topical treatment. Three of 31
centers replied using either a combination of topical
treatment options and systemic treatment with steroids
or topical treatment only. One center used solely
systemic treatment for treatment of mild cGVHD
despite available topical treatment options. If visceral
manifestations are present in mild cGVHD, half of
the centers (15 of 31) replying to the survey stated using
systemic application of steroids \0.5 mg/kg/day,
whereas 14 of 31 centers stated using steroid doses be-
tween 0.5 and 1 mg/kg/day. Seven centers used partly
an alternative approach, with 1 center using ECP
only and 1 center combining CsA with MMF and in
the presence of liver involvement with ursodeoxycholic
acid, or CsA in combination with steroids. One center
stated the use of a pulse of steroids.
Treatment of moderate/severe cGVHD
Half of the centers (16 of 31) stated using predni-
sone or methylprednisone with a dose range of 0.5 to
1 mg/kg/day for treatment of moderate cGVHD and
normal platelet counts. Four of 31 centers stated using
an initial dose of steroids not exceeding 0.5mg/kg/day.
One-third of the centers (11 of 31) stated using the
combination of a CNI and steroids. One center used
steroids in combination with MMF, whereas 2 centers
combine steroids not exceeding 0.5 mg/kg/day with
topical immunosuppressants. In the presence of low
platelets at diagnosis of cGVHD 20 of 31 responding
centers would combine steroids with CNI.
With regard to the type of steroid used, 16 of the
centers reported the use of prednisone only, 7 centers
reported using methylprednisolone only, and 8 addi-
tional centers stated using prednisone aswell asmethyl-
prednisolone. Other steroids are not used.With regard
to the distribution of the steroid dose, 19 centers stated
the application of the total steroid dose once daily in the
morning. Fifteen centers divide the steroid dose into 2
doses given in the morning and noon (n 5 4) or in the
morning andat night (n511).Twocenters split the ste-
roid dose into 3 doses given at morning, noon, and
night. Three centers applied 2 different schedules and
were counted twice. Six centers stated using daily appli-
cationof steroids until completewithdrawal. Seven cen-
ters attempt to use an every other day schedule at dosesabove 0.25 mg/kg/day prednisone/methylpredniso-
lone, whereas 18 centers stated using an every other
day schedule after dose reduction below 0.25 mg/kg/
day. Several centers stated using an every other day
schedule especially after reaching doses below10mg af-
ter long exposure to steroids. Regarding the initial dose
of steroids, 25 centers applied steroids with an initial
dose#1 mg/kg/day. Nine centers stated using initially
higher doses for longer than 1 week and 3 centers used
both approaches) Ten centers reported on the occa-
sional use of pulsing steroids (.2 mg/kg/day predni-
sone/methylprednisolone) for \1 week to induce
rapid symptom control.
With regard to the start of the steroid taper in
a patient being in CR of cGVHDafter 2 weeks of treat-
mentwith prednisone 1mg/kg/day, 26 centers stated to
start the taper of the steroid dose, whereas 4 centers
would continue for another 4 weeks with 1 mg/kg/
day prednisone before dose reduction. One center
would continue 1mg/kg/day for at least 3 months after
achieving remission of cGVHD before start of dose
reduction.
Treatment of progressive onset of cGVHD
Most of the centers (18 of 31) increase the steroid
dose if progression to cGVHD in the absence of low
platelets is diagnosed, continue the CNI, and start
a new agent (ECP [n5 9] orMMF [n5 12]). Other cen-
ters would add an mTOR inhibitor (sirolimus [n 5 1],
everolimus [n 5 1[), or change the CNI from CsA to
FK506 (n5 1). In addition, the use of antibodies includ-
ing rituximab and antithymocyte globulin (ATG) and
topical treatment with ultra violet AUVA or psoralen
UVA(PUVA)photochemotherapywere reportedby sin-
gle centers. Five centers stated to continue steroids and
theCNIwith the same dose and addMMF (n5 4) or ur-
sodeoxycholic acid. Eight centers reported an increased
dose of steroids only. Three centers would continue the
same dose of steroids, stop the CNI, and add either
MMF or an mTOR inhibitor or ECP. One center con-
sidered the use of alemtuzumab as combination partner.
Three centers would increase the steroid dose, stop the
CNI, and add either ECP (n5 2) or rituximab (n 5 1).
One center considered the use of etanercept. The con-
comitant presence of low platelets did not influence the
treatment.Topical Treatment (Table 5)
Although cGVHD is regarded as a systemic dis-
ease of complex pathophysiology, local manifestations
may be treated with topical immunosuppression. Mild
cGVHD may be accessible by topical treatment (oral
mucosa, skin) and may not require systemic immuno-
suppression [8]. Topical treatment of mild cGVHD is
even more important in patients with high risk of re-
lapse, as mild cGVHD is associated with a decreased
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interfere with the graft-versus-malignancy effect [2].
Solely topical treatment requires close follow-up of
patients to avoid progression to other organs outside
the region treated topically.
In moderate and severe cGVHD topical immuno-
suppression may be used as an adjunct to increase local
response rates as well as to fasten local responses. This
is of special importance in oral manifestations of
cGVHD. Phototherapy of skin lesions may be another
situation where topical immunosuppression may be
added to systemic treatment. A third indication for top-
ical treatment may be a mixed response on systemic im-
munosuppressionwith a good response atmost sites but
remaining symptoms at a single site that can be reached
with topical treatment. This is of special relevance in
oral and local cutaneous manifestations of cGVHD.
Moreover, topical immunosuppressive therapies
for cGVHD are associated with less toxicity compared
to systemic treatment. Their use can improve response
rates and thus facilitate dose reduction, reduce toxicity,
or even help circumvent the application of systemic
drugs in cases of mild cGVHD.
Topical immunosuppressionmay further be an im-
portant therapeutic approach to manifestations of
cGVHD that can be reached topically in the presence
of relapse of the underlying malignancy.
Especially for topical therapy, the parents’ assis-
tancemay be necessary for children to improve compli-
ance. An additional aspect of topical treatment in
children is the risk of reaching significant systemic
drug levels in small infants receiving topical treatment
with steroids or CNIs.Cutaneous cGVHD
Cutaneous manifestations of cGVHD are not only
the most frequent manifestations in cGVHD, but often
the onlymanifestation of cGVHD.Although lichenoid-
type changes represent the early form of skin involve-
ment of cGVHD, late manifestations of cGVHD may
lead to superficial and subsequent deep sclerosis of the
dermal layer resembling systemic sclerosis and are
associated with major impairment of quality of life as
well as of activity. Because the cutaneousmanifestations
can be easily reached by topical treatment, as for other
skin diseases, a number of effective topical treatment
options are available. Topical treatment of cutaneous
manifestations of cGVHD may be the only treatment
given or may be applied in addition to systemic immu-
nosuppression to speed up response or to spare systemic
immunosuppression (steroids). Another indication may
bemixed response to systemic immunosuppressionwith
active dermal manifestations persisting. One special
aspect of topical treatment of cutaneous manifestations
of cGVHD is the large surface potentially involved.
Although UV-based treatment options may reach thewhole body surface, ointments may not be feasible.
Even more, topical steroids as well as topical CNIs
applied to extended areas may have systemic side effects
counteracting with the aim of targeting solely the skin
[89-91].
Cutaneous PUVA (C-1 III-1)
The combination of UVA light with the photosen-
sitizer 8-methoxypsoralen (PUVA) represents a stan-
dard treatment for a number of dermatologic diseases,
such as psoriasis, cutaneous T cell lymphoma, lichen
planus, and localized scleroderma. PUVA has been
evaluated in cutaneous manifestations of cGVHD in
a number of retrospective studies and prospective trials
[26-31]. Vogelsang et al. [31] reported a retrospective
analysis of 40 patients treated with PUVA demonstrat-
ing a high local response rate (31 of 40 patients). PUVA
is generally well tolerated with a high response rate in
the skin and mild side effects. Notably, the effect of
PUVA was only local, as cutaneous response did not
correlate with response of other organ manifestations.
Comparable results were observed in other trials
[26,27,30,31,92]. Eight-methoxypsoralen (8-MOP,
Meladinine) is given orally 2 hours beforeUVA expo-
sure at a dose of 0.6 mg/kg. Alternatively it may be ap-
plied topically using cream containing 8-MOP (dose
range: 0.005-0.0006%8-MOP)orbathwith a final con-
centration ranging from 0.5 to 1 mg/l 8-MOP. After
oral treatment with 8-MOP exposure, a UV skin and
eye protection with UVA blocking sunglasses is re-
quired for 24 hours. Treatment is given typically on 3
to 4 days per week and frequency is reduced once stable
response is achieved. The initial dose depends on the
skin type ranging from 0.5 J/cm2 to 1 J/cm2. PUVA is
mainly effective in lichenoid cGVHD. Sclerodermoid
manifestations of cGVHDrespond poorly and show in-
creased phototoxicity. Of note, drugs like voriconazole
or cotrimoxazole are associated with increased photo-
toxicity and photoallergies and must not be given dur-
ing treatment with UV light. Potential side effects of
oralmethoxypsoralenmay be nausea andmild elevation
of liver enzymes, which has not been observed in topical
application of the drug.Overall, PUVA is a useful treat-
ment of cutaneous manifestations of cGVHDwith low
side effects taking into account the short-term risk for
phototoxicity and potential long-term risk of the induc-
tion of basal cell carcinoma.
UVA1 (C-1 III-1)
UVA1, emitting exclusively in the long-wave UVA
range (UVA1: 340-400 nm), is a well-established treat-
ment in sclerosing skin diseases and has been used
occasionally in treatment of cutaneous manifestations
of cGVHD. Calzavara et al. [32] reported 9 patients
treated for cutaneous manifestations of cGVHD,
with 4 having lichenoid and 5 with sclerodermoid
1620 Biol Blood Marrow Transplant 16:1611-1628, 2010D. Wolff et al.manifestations. All patients responded, and CRs were
reached in 5 patients including patients with scleroder-
moid manifestations. A second retrospective analysis
published by Wetzig at al. [34] reported on the results
of UVA1 treatment of 10 patients with cGVHD
(lichenoid, n5 7, sclerodermoid, n5 3) demonstrating
CRs in 6 patients, partial responses (PRs) in 3 patients,
and minor improvement in the remaining patient.
Comparable results were achieved in other groups
[33,35]. The UVA1 dose was 50 J/cm2 given on 3
days per week. Relapses of cGVHD became manifest
if treatment was terminated too early. The advantage
of high-dose UVA1 is the avoidance of a photosensi-
tizer without need for UV protection and no systemic
side effects associated with the latter. Again, drugs
with phototoxicity and a high rate of photoallergies
must not be given during treatment.
UVB (C-1 III-2)
Narrow-bandUVB (311 nm) and broad bandUVB
(280-320 nm) are increasingly used in the treatment of
dermatologic diseases including cutaneous manifesta-
tions of cGVHD. However, published evidence is
rather limited. In 1998, Enk et al. [36] reported a series
of 5 patients treated with broadbandUVB for lichenoid
(n5 3) or sclerodermoid cGVHD. Although 2 patients
with lichenoid manifestations responded, no response
was achieved in sclerodermoid cGVHD. The latter
was confirmed by other groups. The failure in sclero-
dermoid cGVHD may be because of the limitation of
the effect of UVB on epidermis. In contrast to UVA1
and PUVA, UVB does not reach the dermal layer
involved in sclerodermoid cGVHD. UVB is typically
given 3 to 5 times per week and the only short-term
risk is phototoxicity especially when patients are taking
photosensitizing drugs. As potential long-term risk,
cutaneous malignancies have to be kept in mind.
Topical Tacrolimus (Protopic) (C-1 III-1)
The topical CNI FK506 (Protopic 0.1%) is
a well-established treatment in atopic dermatitis and
was occasionally used in the treatment of cutaneous
manifestations of cGVHD. Elad et al. [23] reported
a retrospective analysis of 10 patients with steroid-
dependent cutaneous cGVHD. Treatment was given
in different combinations with systemic immunosup-
pression. Significant responses were achieved in 7 pa-
tients including 1 CR. Treatment consisted of topical
FK506 (Protopic) initially applied 2 to 3 times per
day at a concentration of 0.03%. The dose was
increased to 0.1% if well tolerated. Choi and Nghiem
[22] reported on a series of 18 patients receiving topical
tacrolimus 0.1% for cutaneous manifestations of
cGVHD demonstrating a response rate of 72% with
erythema and pruritus responding rapidly. Of note
was a high rate of subsequent progression of cGVHDat other sides and loss of efficacy in 2 patients requiring
intensification of systemic immunosuppression or in-
troduction of PUVA. The advantage of topical FK506
is the avoidance of systemic side effects of CNIs, which
is of special relevance in patients intolerant to systemic
CNI.Moreover, short-term toxicity as seen for steroids
with skin atrophy is basically absent, whereas the major
potential long-term risk is the increased rate of cutane-
ous malignancies.
Pimecrolimus (Elidel) (C-1 III-1)
Like topical FK506, pimecrolimus is a well-
established drug in the treatment of atopic dermatitis
and was occasionally used in treatment of cutaneous
manifestations of cGVHD. Ziemer et al. [25] reported
a case of an infant suffering from refractory lichenoid
cGVHD who achieved a CR. Comparable results have
been achieved by other groups [24,93]. A potential
advantage when compared to FK506 is the improved
local tolerability. Topical CNI are of special relevance
in areas where potent topical steroids should be
avoided, such as in facial cGVHD involvement.
Topical Steroids (C-1III-1)
Although topical steroids are standard of care in
numerous skin diseases, they have not been systemati-
cally evaluated in cutaneous manifestations of
cGVHD. Nevertheless, topical steroids are frequently
used in the treatment of cutaneous manifestations of
cGVHD [7]. Generally, topical steroids are well toler-
ated; some long-term risks need to be taken into
account as steroids may increase the risk for cutaneous
infections and interferewith skin healing, and therefore
must not be used in the presence of skin break down.
Moreover, topical steroids may lead to skin atrophy.
In general, neck-down areas may be treated with mid-
dle or upper mid-strength steroids; the latter should
not be given for longer than 2 weeks. Facial manifesta-
tions should be solely treated with low potency topical
steroids (hydrocortisone 1%) limited to a restricted
time. In the case of a prolonged need for topical treat-
ment of facial involvement, topical CNI should be con-
sidered instead. Of special relevance is the larger skin
surface area-to-body weight ratio in children, increas-
ing the risk for systemic side effects of topical steroids.
Oral Mucosal Manifestations of cGVHD
The oral cavity is themost frequent site of cGVHD
involvement using BM transplantation (BMT) and the
secondmost frequently involved site usingPBSC trans-
plantation (PBSCT) [94]. Moreover, oral cGVHD is
often refractory to systemic therapies and does not cor-
relate with severity of systemic manifestations; thus,
complementary topical treatment is required [95]. If
cGVHD only affects the oral mucosa, topical treat-
ment may prevent the severe side effects associated
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of the oral mucosa are frequently present in patients
with cGVHD, sufficient diagnostic procedures and
prophylactic oral hygiene has to be performed.
Budesonide (C-1 III-1)
Budesonide is a corticosteroid with low bioavail-
ability when absorbed through the oral mucosa, mini-
mizing the risk for systemic side effects. Budesonide
has been used for the treatment of oral manifestations
of cGVHD. In a report byElad et al. [40], all 12 patients
responded to the budesonide mouthwash, including 7
with “good” or “complete” recovery as scored by both
examiner and subject. An early response noted within
the first 2 to 3 weeks of treatment was complemented
by a probable cumulative effect seen during the first
months of treatment. Sari et al. [41] reported on a retro-
spective matched pair analysis comparing systemic
immunosuppression without (n 5 12) or with addi-
tional budesonide (n 5 11), showing a significant de-
crease in median oral cGVHD examination scores
between the 2 groups. The overall response rate was
83% in the budesonide group compared to 36% in
the control group. The efficacy of budesonide was con-
firmed in a case report published by Utsman et al. [43].
Pharmacokinetic studies of budesonide in patients with
cGVHD and healthy individuals showed that only 2%
of a buccal dose of budesonide achieved systemic circu-
lation in healthy individuals. However, in patients with
oral cGVHD, the percentage was 10%, probably
because of alterations in drug uptake and metaboliza-
tion [96]. A formal phase II trial evaluating the efficacy
of budesonide in this context has recently been finished;
final results are pending. A phase III trial evaluating
the efficacy of budesonide in an effervescent tablet
formulation in oral manifestations of cGVHD is cur-
rently ongoing (BUM-5/GVH). Until commercially
available, Budenofalk capsules need to be crushed
and dissolved in 5 to 10 mL of water. Oral rinsing
should be performed 3 times per day over a time span
of 10 minutes. Because topical steroids increase the
risk for fungal overgrowth, an antifungal prophylaxis
should be added.
Dexamethasone (C-1 III-2)
Topical dexamethasone was evaluated in a retro-
spective analysis of 16 patients with oral manifestations
of cGVHD[44].Treatmentwith topical corticosteroids
consisted of 0.1 mg/mL dexamethasone mouth wash 4
times a day in combination with antifungal prophylaxis.
Nine patients showed complete remission, 2 improved,
and 5 did not respond, demonstrating that topical
dexamethasone is effective in oral manifestations of
cGVHD with few side effects [44]. The use of higher
concentrations of dexamethasone (0.4mg/mL)was sug-
gested [42]. Currently, a phase II trial headed by theDana-Farber Cancer Institute (NCT00686855) com-
pares topical dexamethasone with topical tacrolimus.
Because dexamethasone mouth wash is not commer-
cially available, it needs to be prepared on an individual
formulation.
Topical Triamcinolone Fluocinonide,
Clobetasole, Betamethasone Dipropionate,
Prednisolone (C-1 III-3)
Topical triamcinolone adhesive ointment has been
developed and is approved for treatment of noninfec-
tious inflammatory conditions of the oral mucosa [97].
It is frequently used in treatment of oral manifestations
of cGVHD, although no formal evaluation of effective-
ness has been performed so far. It has to be applied to
involved areas of the oral mucosa 1 to 2 times per day.
Other topical steroids used in inflammatory conditions
of the oral mucosa are fluocinonide, clobetasole, beta-
methasone dipropionate, and prednisolon in different
formulations [42].
Topical Cyclosporine (C-2 III-1)
Topical cyclosporine mouth rinses are occasion-
ally used in the treatment of oral manifestations of
cGVHD. Epstein et al. [47] reported a retrospective
analysis on the topical use of cyclosporine in 11 pa-
tients failing prior treatment of cGVHD including
the use of topical dexamethasone. Treatment consisted
of cyclosporine mouth rinses performed twice daily.
Seven out of 11 patients responded. A second trial eval-
uated the use of cyclosporine administered in an adhe-
sive hydroxypropyl cellulose base in patients with oral
lichenoid reactions that remained active despite prior
use of high-potency topical steroids and in some cases
despite the combined use of topical and systemic
immunosuppression. Signs and symptoms of ulcera-
tive oral GVHD improvedmore than 50% in 3 of 4 pa-
tients treated with the addition of topical cyclosporine
[48]. The topical use of cyclosporine may represent
a useful adjunctive approach in the management of
oral lichenoid reactions, although dose-finding and
placebo-controlled studies are needed. It should be
noted that cyclosporine has been associated with an
increased risk of secondary malignancies, although
there is no good evidence for either supporting or
ruling out the malignant potential following topical
oral application [98].
Topical FK506 (C-2 III-1)
Because FK506 is successfully used in systemic
prevention and treatment of GVHD, it has been also
applied for topical treatment of oral manifestations
of cGVHD. Eckardt et al. [46] reported 3 patients
with refractory oral manifestations responding to the
oral application of an FK506 containing ointment
(Protopic 0.1%). The ointment was applied to
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could show the long-term efficacy of topical tacroli-
mus in 3 patients with oral lesions of cGVHD. Albert
et al. [45] reported on the results of a pilot trial evalu-
ating FK506 in treatment of oral manifestations of
GVHD in 6 children showing a complete response
or a very good partial response in 4 patients and partial
response in the remaining 2 patients. Sanchez et al.
[51] topically applied 0.1% FK506 ointment 3 times
a day for 2 months, which resulted in the complete
resolution of oral lesions. Of interest was the systemic
drug absorption in some patients. Recently, a combina-
tion protocol composed of dexamethasone rinse (0.5
mg/5mL) and FK506 solution (0.5 mg/5mL) was sug-
gested [50]. Currently, topical FK506 is compared in
a randomized phase II trial against dexamethasone
(NCT00686855). Because Protopic has been origi-
nally developed for application to the skin, individual
formulations of tacrolimus for treatment are used
[50]. Because in cutaneous cGVHD and other skin
diseases the use of CNI has been associated with an in-
creased risk for epidermalmalignancies, a cancerogenic
potential of topical application of FK506 or CsA has to
be considered when used in the oral cavity as well and
requires follow-up visits.
Oral Phototherapy: PUVA/UVB (C-2 III-1)
The positive results of PUVA treatment for cutane-
ous cGVHD led to the evaluation of the efficacy of in-
traoral PUVA. In a retrospective analysis, 7 patients
with oral manifestations of cGVHD received intraoral
PUVA [44]. Methoxypsoralen was given at a reduced
dose of 0.3 mg/kg 1 hour before UVA exposure. A glass
fiber extension of an UVA source was used for manual
intraoral application of 0.5 J/cm2. Treatment was given
on 3 to 4 days per week and theUVA dose was raised by
0.5 J/cm2 if tolerated. Four of 7 patients showed local
CR and 2 improved, whereas 1 did not respond.
Responses were achieved despite prior resistance to sys-
temic immunosuppressive treatment, and the efficacy of
intraoral PUVA was confirmed by 2 case reports
[53,54]. Elad et al. [52] reported on the use of intraoral
UVB, which does not require exposure to a photosensi-
tizing agent and showed a response in both patients
treated. Low-level laser therapy may be an additional
treatment for oral manifestations of cGVHD [99].
Intestinal GVHD
As in other organ manifestations, topical treatment
may also be an option for intestinal cGVHDused either
in combination with a systemic immunosuppressive
agent or as single agent in mild manifestations solely
restricted to the intestinal tract.Despite its documented
clinical efficacy, topical treatment of intestinal manifes-
tations may be rather symptomatic and does not target
the underlying systemic pathophysiology. Therefore,a close follow-upof all other organs potentially involved
in cGVHD is mandatory. Moreover, topical treatment
with steroids requires the understanding of the site of
action in the intestinal tract of the agent used. For
instance, budesonidegivenorally does not reach thedis-
tant part of the large bowel, and capsules may not work
in esophageal manifestations of cGVHDbecause of the
lack of exposure.
Budesonide (C-1 III-2)
The application of beclomethasone in the treat-
ment of intestinal aGVHD and the positive results of
topical budesonide in the treatment of oral manifesta-
tions of cGVHD led to the use of budesonide for treat-
ing intestinal manifestations of cGVHD [100,101]. A
retrospective analysis evaluated the efficacy of
budesonide in gastrointestinal (GI) cGVHD in 13
patients. Treatment consisted of budesonide with an
initial daily dose of 3  3 mg orally. Complete resolu-
tion was achieved in 7 patients, and 1 patient achieved
partial remission of cGVHD. One patient achieved
aCR ofGImanifestations, whereas systemicmanifesta-
tions remained stable. Relapse of GVHD symptoms
occurred afterwithdrawal of immunosuppression (n5 3)
as well as progression of GVHD at other sides (n 5 3),
indicating a dominating local effect of budesonide.
Despite these limitations, budesonide represents a treat-
ment option inmild tomoderate cGVHD, which is well
tolerated [37].
Beclomethasone (C-1 III-1)
Beclomethasone dipropionate has been evaluated
in primary treatment of intestinal aGVHD and is asso-
ciated with an increased response rate as well as better
survival compared to solely systemic steroids [101].
Iyer et al. [38] reported on a compassionate use study
using beclomethasone for treatment of intestinal man-
ifestations of cGVHD after failure of systemic first-
line treatment in the context of flaring symptoms after
reduction of immunosuppression. Thirteen patients
received beclomethasone 4  2 mg (solution on corn
oil), whereas systemic immunosuppression consisting
of CsA and methylprednisone was continued. Three
patients showed CR and 6 additional patients re-
sponded partially, whereas 4 patients did not respond.
A recent report confirmed the high efficacy of beclo-
methasone in treatment of GI manifestations of
cGVHD in a series of 33 patients demonstrating a re-
sponse rate of 86% [39]. Therefore, beclomethasone
may be a useful topical treatment in intestinal manifes-
tations of cGVHD with only little systemic effects.
Ocular Manifestations of cGVHD
Eye involvement is a frequent manifestation in
cGVHD leading to significant impairment of quality
of life because of blurred vision, pain, photophobia,
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toms of ocular GVHD include acute conjunctival
inflammation, pseudomembranous, and cicatricial
conjunctivitis as well as keratoconjunctivitis sicca syn-
drome and associated corneal complications such as
persistent epithelial defects and corneal ulcers. The
latter is often irreversible because of destruction of
the lacrimal glands. Besides supportive treatment in-
cluding lubrication with preservative artificial tears as
well as control of drainage with punctal plugs, topical
immunosuppression may improve symptoms of ocular
involvement of cGVHD [10].
Topical Steroids (C-1 III-1)
Robinson et al. [56] reported a series of 7 patients
with cicatricial conjunctivitis as manifestation of
cGVHD. Two of them received exclusively topical
treatment, whereas 5 patients had been treated with
additional systemic immunosuppression without local
response. Treatment consisted of prednisolone acetate
1% eye drops applied to the conjunctiva initially 4/
day with subsequent reduction of frequency. CRs were
achieved in all patients. One patient experienced a flare
of symptoms after 6 months and responded to a second
course. Although symptoms of inflammation resolved,
no effect was achieved with respect to tear production.
A second trial evaluated the efficacy of topical
methylprednisolone in the treatment of ocular mani-
festations of Sjo¨gren’s syndrome in 21 patientsda
condition comparable to ocular involvement of
cGVHD [55]. Methylprednisolone sodium succinate
1% eye drops were applied to the conjunctiva initially
3 to 4/day with reduction of frequency after 2 weeks.
CRs were achieved in 57% of patients, and the remain-
ing 43% showed significant improvement of symp-
toms. Comparable results have been achieved with
dexamethasone containing eye drops (Dexa sine).
Side effects of using topical steroids in the treatment
of ocular manifestations of cGVHD are corneal thin-
ning, infectious keratitis, ocular hypertension, and
glaucoma and cataract development. Therefore, the
use of topical steroids should be limited to a short pe-
riod of time and requires a close follow-up with an
ophthalmologist.
Topical CsA (C-1 III-1)
As for oral cGVHD, topical CsA may improve
symptoms of ocular involvement of cGVHD. The
largest series of patients with sicca syndrome partly as-
sociated with Sjo¨gren’s syndrome (31%) evaluated 877
patients in a placebo-controlled double-blind random-
ized trial [59]. Treatment consisted of CsA 0.1% or
0.05% eye drops applied to the conjunctiva 2/day.
Overall, a response rate of 60% was achieved with sig-
nificant improvement of the Schirmer test indicating
recovery of tear production. This correlated withsignificant reduction of symptom burden (OSDI score)
and reduction of corneal staining of dry areas. Interest-
ingly, the lower concentration of CsA (0.05%) achieved
better results and is currently being evaluated in a phase
II trial in prevention of cGVHD after allogeneic
HSCT (NCT00755040) as well as for CsA containing
implants for treatment of dry eye syndrome in associa-
tion with cGVHD (NCT00102583) [102]. Small case
series on ocular manifestations of cGVHD confirm
the efficacy of topical CsA [57,58,60]. Side effects of
treatment are ocular burning or stinging as well as
conjunctival redness in correlation to the CsA dose
used. Given the high efficacy in treatment of dry eye
syndrome as well as cGVHD, CsA 0.05% given 2
times daily may be an effective and safe treatment in
moderate and severe manifestations of cGVHD.Topical Treatment of Pulmonary Manifestations
of cGVHD
Pulmonary manifestions of cGVHD include bron-
chiolitis obliterans (BO), bronchiolitis obliterans with
organizing pneumonia (BOOP), and late interstitial
pneumonitis. Although the underlying pathogenic
mechanisms are poorly understood, especially for BO,
an associationwith cGVHDhasbeen reported [103].Al-
though pathological findings represent the gold stan-
dard criteria for the diagnosis of BO, lung biopsy is
rarely performed in these patients and the diagnosis is
usually based on pulmonary function tests (PFT) and
high-resolution computed tomography (HRCT) [103-
105]. In early BO, bronchiolar inflammation has been
shown to be present [106,107], and therefore, early
treatment may prove more promising than initiation of
therapy once structural, fibrotic changes have occurred.Topical Steroids (B III-2)
In the only study reported to date, Bergeron et al.
[108] retrospectively analyzed the role of topical
treatment early in the course of progressive airflow
obstruction using a combination of budenoside as an in-
halative steroid and formoterol as a long-acting bron-
chodilator. Thirteen patients with mild to moderate
BOwere treatedwith this regimenandshowedadurable
improvement both clinically and in pulmonary function
tests over the follow-up of 12.8 months (5-29 months).
This combined regimen may be a more promising
approach (BIII-2). In contrast to the results in BO after
lung transplantation, a recently published retrospective
analysis on inhaled high-dose fluticasone in treatment
ofBOafter allo-HSCTshowed some efficacy in a group
of 17 patients [109]. Currently a prospective trial
evaluating the efficacy of budesonide and formoterol
in treatment of BO after allo-HSCT is ongoing [110].
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Manifestations of cGVHD
cGVHD of the vulva and vagina is a relatively fre-
quent manifestation of cGVHD and is often associated
with oral and ocular symptoms. Mild manifestations
mayoccasionally remain asymptomatic andaredetected
only by examination, whereas severe manifestations
with sclerosis of vulvar and vaginal tissues lead to severe
architectural changes [10]. Symptomaticmanifestations
should be evaluated and followed by a gynecologist.
Because vulvovaginal manifestations are often not re-
ported spontaneously by patients, careful evaluation of
female patients is required.Although topical or systemic
hormone replacement may improve some symptoms,
a significant proportion of patients require topical
and/or systemic immunosuppression. As in topical
treatment of oral manifestations, exclusion and treat-
ment of coexisting infectious complications is a crucial
part of successful topical treatment.
Topical Steroids (B III-3)
Clobetasol gel (vagina) as well as bethametasone di-
propionate gel (vagina) and ointment (vulva) has been
evaluated in treatment of vulvovaginal manifestations
of lichen planus as well as cGVHD [61,64,111]. In
a cohort of 60 patients receiving intravaginal hydro-
cortisone 25 mg suppositories twice daily, an overall
response rate of 80% was achieved [61]. Clobetasol
has been evaluated in vaginal lichen planus manifesta-
tions as well, and some responses have been reported
[62,63]. Because topical steroids increase the risk for
local infectious complications and especially fungal
infections, adequate monitoring as well as prophylaxis
is crucial.
Topical CNIs (Tacrolimus B III-3, Pimecrolimus
B III-3, and CsA B III-3)
The CNI FK506 (Protopic), pimecrolimus
(Elidel), and CsA have been evaluated in treatment of
vulvovaginal lichen planus-like manifestations as well as
of cGVHD manifestations [63-65]. Interestingly, in
vulvovaginal lichen planus manifestations topical
FK506 had a higher efficacy compared to topical
steroids in terms of symptom relief. The ointment is
usually applied twice daily for 4 weeks with subsequent
taper. Moreover, topical CNIs do not increase the risk
for local fungal and bacterial infections.CONCLUSIONS
cGVHDremains associatedwith significantmorbid-
ity andmortalitybut contributes to improveddisease-free
survival (DFS) after allogeneic HSCT for hematologic
malignancies [2]. Moreover, immunosuppressive treat-
ment is associated with significant long-term sideeffects such as renal insufficiency, osteoporosis/avascular
osteonecrosis of the bone and contributes to infectious
morbidity. Therefore, treatment strategies require a bal-
ance between effective control of cGVHD versus long-
term side effects and the risk to counteract with the
protective GVL effect.
Several controlled trials significantly contributed to
the current knowledge of optimal treatment of
cGVHD, indicating the importance of steroids in
first-line treatment of cGVHD [16-19]. A randomized
trial evaluating the combination of steroids and CsA
indicated a steroid-sparing efficacy but no increase in
response rates for standard risk patients,whereashistor-
ically, patients with low platelets at time of diagnosis of
cGVHD demonstrated an improved outcome with
combination treatment [16,17]. The value of both
controlled trials is limited by the fact that patients
being included received exclusively BM grafts after
MA conditioning regimens and clinical practice
changed considerably during the last 10 years.
Although steroids with or without a CNI are cur-
rently regarded as standard in first-line treatment of
cGVHD, no additional substances such as thalidomide
andMMF given as part of a 3-agent regimen improved
the survival of affected patients [19-21]. Moreover,
azathioprine in combination with steroids impaired
survival because of increased infectious mortality
[18]. Currently, no data are available evaluating the ef-
ficacy of the combination of steroids and MMF.
The use of ECP has been associated with a steroid-
sparing capacity and a favorable side effect profile [80].
Nevertheless, currently no sufficient data are available
to support the use of ECP in first-line treatment.
Therefore, randomized trials evaluating the combina-
tion of steroids with ECP or steroids with MMF are
urgently needed. An additional treatment option,
which may be worth being evaluated in first-line treat-
ment, are mTOR inhibitors, which display therapeutic
activity in cGVHD, although data on the role in first-
line treatment are still lacking.
Topical immunosuppression is an important treat-
ment option for mild manifestations of cGVHD and
may be of significant advantage because of the absence
of systemic side effects. It further does not interfere
with the protective graft-versus-malignancy effect,
and importantly, limited cGVHD has been shown to
result in an improved DFS and OS rates in a number
of diseases [2].
In patients requiring systemic immunosuppression,
topical immunosuppression may be of use to speed up
local response rates and to achieve response in manifes-
tations resistant to systemic immunosuppression. De-
spite the importance of topical immunosuppression so
far, only limited data are available for the majority of
treatment options, and the current knowledge relates
to uncontrolled retrospective case series and personal
experience. Therefore, systematic evaluation of topical
Biol Blood Marrow Transplant 16:1611-1628, 2010 1625First-Line and Topical Treatment of Chronic GVHDimmunosppressive treatment approaches is required
to improve clinical care for affected patients in the
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